December 7, 2017 — Stereotaxis Inc. announced it has received regulatory clearance from Health Canada for its e-Contact Module, which provides physicians with a simple-to-interpret indicator of catheter tip-to-tissue contact. The technology was launched in Europe in June and to date has been utilized in more than 1,300 robotic catheter ablation procedures.
The e-Contact Module is Stereotaxis’ latest technology designed to improve patient outcomes, reduce procedure times and advance automation. Eugene Crystal, M.D., director of arrhythmia services at Sunnybrook Health Sciences Centre in Toronto, and president elect of SCRN, performed the first procedures with the e-Contact module in North America during the week of November 20.
“The latest Stereotaxis innovation adds to the Niobe system’s inherent advantages by providing the ability to accurately determine catheter-to-tissue contact at the point of interest,” said Crystal. “This feature has the capability to further improve robotic magnetic navigation outcomes and efficiency in complex ablation procedures like AF [atrial fibrillation] and VT [ventricular tachycardia] by ensuring first-pass, complete, durable linear lesions.”
For more information: www.stereotaxis.com
October 30, 2024 
